Production of adenovirus vector for gene therapy

Biotechnology Advances

Volumn 20, Issue 7-8, 2003, Pages 475-489

  Nadeau, Isabelle ^a   Kamen, Amine ^a  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

Author keywords

Adenovirus vector; Gene therapy; HEK 293 cells; Scale up; Viral vectors production

Indexed keywords

GENES; GENETIC ENGINEERING; METABOLISM; PHYSIOLOGY; TUMORS;

ADENOVIRUS VECTORS;

BIOTECHNOLOGY;

GENETICS;

ADENOVIRIDAE;

EID: 0037215640     PISSN: 07349750     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0734-9750(02)00030-7     Document Type: Review

References (61)

1. Bibila T.A., Ranucci C.S., Glazomitsky K., Buckland B.C., Aunins J.G. Monoclonal antibody process development using medium concentrates. Biotechnol. Prog. 10:1994;87-96.
2. Bonifas V.H. Time-course and specificity of the arginine requirement for adenovirus biosynthesis. Arch. Gesamte Virusforsch. 20:1967;20-28.
3. Carmen I.H. A death in the laboratory: the politics of the gelsinger aftermath. Mol. Ther. 3:2001;425-428.
4. Chaubard J.F. Serum-free media and bioreactor strategies for manufacturing adenoviral gene therapy vectors. Viral vectors. Viral vectors and vaccines, Lake Tahoe, NV, Nov. 6-9:2000.
5. Côté J., Garnier A., Massie B., Kamen A. Serum-free production of recombinant proteins and adenoviral vectors by 293SF cells. Biotechnol. Bioeng. 59:1998;567-575.
6. Danthinne X., Imperiale M.J. Production of first generation adenovirus vectors: a review. Gene Ther. 7:2000;1707-1714.
7. Fallaux F.J., Bout A., Van der Veld I., Van den Wollenberg D.J., Hehir K.M., Keegan J.et al. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum. Gene Ther. 9:1998;1909-1917.
8. Garnier A., Cote J., Nadeau I., Kamen A., Massie B. Scale-up of the adenovirus expression system for the production of recombinant protein in human 293S cells. Cytotechnology. 15:1994;145-155.
9. Garnier A., Cortin V., Thibault J., Jacob D. Production of recombinant adenovirus by 293 cells cultures in perfusion. Cell culture engineering VIII, April 1-6, 2002, Snowmass, Colorado:2002.
10. Gilbert P.A., Garnier A., Jacob D., Kamen A. On-line measurement of GFP fluorescence for the monitoring of recombinant adenovirus production. Biotechnol. Lett. 22:2000;561-567.
11. Glacken M.W., Adema E., Sinskey A.J. Mathematical descriptions of hybridoma culture kinetics:1. Initial metabolic rates. Biotechnol. Bioeng. 32:1998;491-506.
12. Graham F.L. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36:1977;59-74.
13. Green M. Biochemical studies on adenovirus multiplication. Xll. Plaquing efficiencies of purified human adenovirus. Virology. 31:1967;562-565.
14. Green M. Effect of oncogenic DNA viruses on regulatory mechanisms of cells. Fed. Proc. 29:1970;1265-1275.
15. Hassel T., Gleave S., Butler M. Growth inhibition in animal cell culture. Appl. Biochem. Biotechnol. 30:1990;29-40.
16. Hehir K.M., Armentano D., Cardoza L.M., Choquette T.L., Berthelette P.B., White G.A.et al. Molecular characterization of replication-competent variants of adenovirus vectors and genome modications to prevent their occurrence. J. Virol. 70:1996;8459-8467.
17. Heilman C.A., Rouse H. Adenovirus Type 2 polypeptide synthesis in arginine-deprived cells. Virology. 105:1980;159-170.
18. Hodge L.D., Scharff M.D. Effect of adenovirus on host cell DNA synthesis in synchronized cells. Virology. 37:1969;554-564.
19. Hutchins B. Bioprocess. J. 1:2002;25-28.
20. Imler J.L., Chartier C., Dreyer D., Dieterlé A., Sainte-Marie M., Faure T.et al. Novel complementation cell lines derived from human lung carcinoma A549 cells support the growth of E-1 deleted adenovirus vectors. Gene Ther. 3:1996;75-84.
21. Irish T., Baker W., Fresner B., Abraham G., Tvijn C., Lardenoije R.et al. A comparative study of large-scale production strategies used to produce RCA free adenovirus preparations in Serum-Free Media. Research Report. 2000;JRH Bioscience, Lenexa, KS, USA.
22. Iyer P., Ostrove J.M., Vacante D. Comparison of manufacturing techniques for adenovirus production. Cytotechnology. 30:1999;169-172.
23. Jardon M., Garnier A. pH, PCO2, and temperature effects on adenovirus production. Cell culture engineering VIII, April 1-6, 2002, Snowmass, Colorado:2002.
24. Keegan J.S. Cell scale-up and infection for the production of adenoviral gene therapy vectors. Viral Vectors and Vaccines, Williamsburg, Virginia, Nov 1-4, 1999:1999.
25. Klyushnichenko V., Bernier A., Kamen A., Harmsen E. Improved high-performance liquid chromatographic method in the analysis of adenovirus particles. J. Chromatogr., B. 755:2001;27-36.
26. Kumel G., Hamer H.J. The influence of arginine starvation on the synthesis of virus high molecular weight DNA in hela cells productively infected by adenovirus type 5. J. Gen. Virol. 45:1979;599-610.
27. Lehmberg E., Traina J.A., Chakel J.A., Chang R.J., Parkman M., McCaman M.T.et al. Reversed-phase high-performance liquid chromatographic assay for the adenovirus type 5 proteome. J. Chromatogr., B. 732:1999;411-423.
28. Leopold P.L., Ferris B., Grinberg I., Worgall S., Hackett N.R., Crystal R.G. Fluorescent virions: dynamic tracking of the pathway of adenoviral gene transfer vectors in living cells. Hum. Gene Ther. 9:1998;367-378.
29. Lin A. Development of scaleable manufacturing processes for retroviral, adenoviral and adeno-associated viral vectors. Viral Vectors and Vaccines, Williamsburg, Nov. 16-19, 1998:1998.
30. Liu LC, Shoupeng L. Method of Producing Adenoviral Vector Stocks. US Patent No. 6168941 B1, Jan 2001.
31. Lochmuller A.J., Jani A., Huard J.J., Prescott M.S., Massie B., Karpati G.et al. Emergence of early regionn 1-containing replication-competent adenovirus in stocks of replication-defective adenovirus recombinants (ΔE1+ΔE2) diring multiple passages in 293 cells. Hum. Gene Ther. 5:1994;1485-1491.
32. Lusky M., Christ M., Rittner K., Dieterle A., Dreyer D., Mourot B.et al. In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted. J. Virol. 72:1998;2022-2032.
33. Maizel J.V., White D.O., Scharff M.D. The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A and 12. Virology. 36:1968;115-125.
34. McQueen A., Bailey J.E. Effect of ammonium ion and extracellular pH on hybridoma cell metabolism and antiboy production. Biotechnol. Bioeng. 35:1990;1067-1077.
35. Mittereder N., March K.L., Trapnell B.C. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J. Virol. 70:1996;7498-7509.
36. Murakami P., McCaman M.T. Quantitation of adenovirus DNA and virus particles with the picoGreen fluorescent dye. Anal. Biochem. 274:1999;283-288.
37. Nadeau I., Garnier A., Côté J., Massie B., Chavarie C., Kamen A. Improvement of recombinant protein production with the human adenovirus/293S expression system using fed-batch strategies. Biotechnol. Bioeng. 51:1996;613-623.
38. Nadeau I., Jacob D., Perrier M., Kamen A. 293SF metabolic flux analysis during cell growth and infection with an adenoviral vector. Biotechnol. Prog. 16:2000;872-884.
39. Nadeau I., Sabatié J., Koehl M., Perrier M., Kamen A. Human 293 cell metabolism in low glutamine-supplied culture: interpretation of metabolic changes through metabolic flux analysis. Metab. Eng. 2:2000;277-292.
40. Nadeau I., Seanez G., Wu F. Adenovirus production in 293 cells: a comparative study between a suspension cell and an adherent cell process. The 17th ESACT Meeting, Tylosand, Sweden, June 10-14:2001.
41. Nadeau I., Gilbert P.A., Jacob D., Perrier M., Kamen A. Low-protein medium affects the 293SF central metabolism during growth and infection with adenovirus. Biotechnol. Bioeng. 77:2002;91-104.
42. Nadeau I., Seanez G., Wu F. Optimization of a 293 suspension process for adenovirus production. Cell Culture Engineering VIII, April 1-6, Snowmass, Colorado:2002.
43. Nyberg-Hoffman C., Shabram P., Li W., Giroux D., Aguilar-Cordova E. Sensitivity and reproducibility in adenoviral infectious titer determination. Nat. Med. 3:1997;808-811.
44. Parks R.J., Chen L., Anton M., Sankar U., Rudnicki M.A., Graham F.L. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc. Natl. Acad. Sci. U. S. A. 93:1996;13565-13570.
45. Pina M., Green M. Biochemical studies on adenovirus multiplication. XLV macromolecule and enzyme synthesis in cells replicating oncogenic and nononcogenic human adenovirus. Virology. 38:1969;573-586.
46. Roitsch C., Achstetter T., Benchaibi M., Bonfils E., Cauet G., Gloeckler R.et al. Characterization and quality control of recombinant adenovirus vectors for gene therapy. J. Chromatogr., B. 752:2001;263-280.
47. Rouse C.H., Schlesinger R.W. An arginine-dependent step in the maturation of type 2 adenovirus. Virology. 33:1967;513-522.
48. Russell W.C. Update on adenovirus and its vectors. J. Gen. Virol. 81:2000;2573-2604.
49. Schoofs G., Monica T.J., Ayala J., Horwitz J., Montgomery T., Castillo F.G. A high yielding serum-free, suspension cell culture process to manufacture recombinant adenoviral vectors for gene therapy. Cytotechnology. 28:1998;81-89.
50. Shabram P.W., Giroux D.D., Goudreau A.M., Gregory R.J., Horn M.T., Huyghe B.G.et al. Analytical anion-exchange HPLC of recombinant type-5 adenoviral particles. Hum. Gene Ther. 8:1997;453-465.
51. Transfiguracion J., Bernier A., Arcand N., Chahal P., Kamen A. Validation of a high-performance liquid chromatography assay for the quantification of adenovirus type 5 particles. J. Chromatogr., B. 761:2001;187-194.
52. Trapnell B.C. Adenoviral vectors for gene transfer. Adv. Drug Deliv. Rev. 12:1993;185-199.
53. Vellekamp G., Porter F.W., Sutjipto S., Cutler C., Bondoc L., Liu Y.-H.et al. Empty capsids in column-purified recombinant adenovirus preparations. Hum. Gene Ther. 12:2001;1923-1936.
54. Vorberg S.A., Hunt K.K. Adenoviral gene therapy. Oncologist. 7:2002;46-59.
55. Xie L., Pilbrough W., Metallo C., Zhong T., Pikus L., Leung J.et al. Serum-free suspension cultivation of PER.C6® cells and recombinant adenovirus production under different pH conditions. Biotechnol. Bioeng. 80:2002;569-579.
56. Xie L., Pilbrough W., Metallo C., Warren J., Peltier J., Aunins J.G.et al. Adenovirus process delopment and scale-up for HIV Vaccines production. Cell Culture Engineering VIII, April 1-6, 2002, Snowmass, Colorado:2002.
57. Yeh P., Dedieu J.-F., Orsini C., Vigne E., Denefle P., Perricaudet M. Efficient dual transcomplementation of adenovirus E1 and E4 regions from a 293-derived cell line expressing a minimal E4 functionnal unit. J. Virol. 70:1996;559-565.
58. Wickham T.J. Targeting adenovirus. Millenium review article. Gene Ther. 7:2000;110-114.
59. Wong K., Guardia M.J., Lee S., ahd Hu W.-S. Adenovirus production in 293 Fed-batch cultures. Animal cell technology: products from cells, cells as products. Proceedings of the 16th ESACT Meeting, April 25-29, Lugano, Switzerland:1999.
60. Zhang S, Thwin C, Wu Z, Cho T. An improved method for the production and purification of adenoviral vectors. International Patent, Publication Number WO 98/22588.
61. Zhu J., Grace M., Casale J., Chang A.T.-I., Musco M.L., Bordens R.et al. Characterization of replication-competent adenovirus isolates from large-scale production of a recombinant adenoviral vector. Hum. Gene Ther. 10:1999;113-121.